| Followers | 1128 |
| Posts | 32743 |
| Boards Moderated | 2 |
| Alias Born | 01/11/2016 |
Friday, May 30, 2025 10:44:05 AM
Yeah that is a very good one too.
Recent IVVD News
- Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit • GlobeNewswire Inc. • 04/20/2026 11:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 11:13:22 AM
- Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles • GlobeNewswire Inc. • 04/09/2026 11:01:00 AM
- Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health • GlobeNewswire Inc. • 04/07/2026 11:01:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 08:32:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 08:25:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 08:19:03 PM
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/06/2026 11:01:00 AM
- Invivyd Announces Presentation at the World Vaccine Congress Washington • GlobeNewswire Inc. • 03/30/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 12:11:42 PM
- Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates • GlobeNewswire Inc. • 03/05/2026 12:03:00 PM
- Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 03/05/2026 12:01:00 PM
- Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 • GlobeNewswire Inc. • 03/02/2026 09:10:00 PM
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:01:00 PM
- New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies • GlobeNewswire Inc. • 02/24/2026 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 01:56:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 01:51:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 01:47:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 01:47:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/17/2026 11:39:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/17/2026 11:36:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/17/2026 11:32:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/17/2026 11:26:32 PM
- Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration • GlobeNewswire Inc. • 02/03/2026 12:01:00 PM
